El-Khoueiry, MD, discussed nivolumab plus ipilimumab vs lenvatinib/sorafenib in unresectable HCC. Immunotherapy has become a ...
The FDA has granted fast track designation to the EGFR/HER3 bispecific antibody-drug conjugate (ADC) AVZO-1418 for treatment ...
The FDA approves generic dasatinib tablets, enhancing access and affordability for treating chronic myeloid leukemia and ...
Significant progress in bispecific antibodies, antibody-drug conjugates, and radiopharmaceuticals has been achieved this year ...
The triplet therapy was effective only in patients with nonmutated PIK3CA and ESR1 genes, achieving a median PFS of 9.1 ...
In terms of prognostic risk factors, HER2 positivity, BM surgical resection, and diagnosis after 2014 were associated with ...
Tong Dai, MD: Considering all the options, it looks like if the patient needs faster response, pembrolizumab plus lenvatinib ...
Zelenectide pevedotin (BT8009) demonstrated a well-tolerated safety profile and promising antitumor activity in patients with ...
In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient ...
The investigational combination of bezuclastinib (CGT9486) and sunitinib (Sutent) yielded clinically meaningful benefits with favorable tolerability in patients with gastrointestinal stromal tumors ...
The combination of glofitamab (Columvi) plus polatzumab vedotin (Polivy) demonstrated high efficacy and durable responses in patients with relapsed/refractory large B-cell lymphoma (LBCL), according ...
Join the 43rd Annual Chemotherapy Foundation Symposium in New York City for cutting-edge cancer care education and networking ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback